



February 2009

# GP16-A3

## Urinalysis; Approved Guideline—Third Edition

This document addresses procedures for testing urine, including materials and equipment; macroscopic/physical evaluation; chemical analysis; and microscopic analysis.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in clinical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

## Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: 610.688.0100  
F: 610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-687-5  
ISSN 0273-3099

GP16-A3  
Vol. 29 No. 4  
Replaces GP16-A2  
Vol. 21 No. 19

---

## Urinalysis; Approved Guideline—Third Edition

Volume 29 Number 4

Albert Rabinovitch, MD, PhD  
Lena Arzoumanian, MS, MT(CLS, NCA)  
Krista M. Curcio, MT(ASCP)  
Bill Dougherty  
Abdel-Baset Halim, PharmD, PhD

### Abstract

Clinical and Laboratory Standards Institute document GP16-A3—*Urinalysis; Approved Guideline—Third Edition* is written for laboratory and nonlaboratory personnel responsible for the collection, transport, and analysis of urine specimens. The guideline addresses macroscopic evaluation, chemical analysis, and microscopic examination of urine. The necessary materials and equipment used in the process are considered.

Clinical and Laboratory Standards Institute (CLSI). *Urinalysis; Approved Guideline—Third Edition*. CLSI document GP16-A3 (ISBN 1-56238-687-5). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2009.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2009 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Urinalysis; Approved Guideline—Third Edition*. CLSI document GP16-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.

### **Proposed Guideline**

July 1991

### **Tentative Guideline**

December 1992

### **Approved Guideline**

December 1995

### **Approved Guideline—Second Edition**

November 2001

### **Approved Guideline—Third Edition**

February 2009

ISBN 1-56238-687-5

ISSN 0273-3099

## Committee Membership

### Area Committee on Quality System and Laboratory Practices

**Sheila M. Woodcock, MBA,  
FCSMLS(D)  
Chairholder  
QSE Consulting  
Rose Bay, Nova Scotia, Canada**

**Albert Rabinovitch, MD, PhD  
Co-Vice-Chairholder  
NovoMetrics, Inc.  
Mountain View, California**

**Carl Mottram, BA, RRT, RPFT,  
FAARC  
Co-Vice-Chairholder  
Mayo Clinic  
Rochester, Minnesota**

Eric Arendash, MT(ASCP)  
Centers for Medicare & Medicaid  
Services  
Philadelphia, Pennsylvania

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM  
Quality Systems Consultant  
Broomfield, Colorado

Theresa Billups, MBA, MT(ASCP),  
DLM  
Remel, Inc.  
Lake Charles, Louisiana

Margaret M. Grimes, MD  
Virginia Commonwealth University  
Richmond, Virginia

Devery Howerton, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia

Peter L. Minetti, CQA, CQE,  
CQMgr(ASQ)  
Fujirebio Diagnostics, Inc.  
Malvern, Pennsylvania

Bruce D. Tually, BAppSc, MAppSc  
Hunter Area Pathology Service  
New South Wales, Australia

#### Advisors

Kay M. Creed  
St. Mary's Hospital  
Richmond, Virginia

Dennis J. Ernst, MT(ASCP)  
Center for Phlebotomy Education  
Ramsey, Indiana

Steven I. Gutman, MD, MBA  
FDA Ctr. for Devices/Rad. Health  
Rockville, Maryland

Stephen J. Sarewitz, MD  
Valley Medical Center  
Renton, Washington

Jennifer Schiffgens, MBA, MT(ASCP)  
California Pacific Medical Center  
San Francisco, California

Daniel W. Tholen, MS  
Dan Tholen Statistical Consulting  
Traverse City, Michigan

#### Staff

Clinical and Laboratory Standards  
Institute  
Wayne, Pennsylvania

Lois M. Schmidt, DA  
*Vice President, Standards  
Development and Marketing*

Jennifer K. McGeary, MT(ASCP),  
MSHA  
*Staff Liaison*

Melissa A. Lewis  
*Editor*

### Acknowledgment

CLSI and the Area Committee on Quality Systems and Laboratory Practices gratefully acknowledge the experts listed below for their help in preparing the approved-level, third edition of this guideline.

Albert Rabinovitch, MD, PhD; NovoMetrics, Inc.  
Lena Arzoumanian, MS, MT(CLS, NCA); BD Diagnostics, Preanalytical Systems  
Krista M. Curcio, MT(ASCP); Sysmex America, Inc.  
Bill Dougherty; International Remote Imaging Systems  
Abdel-Baset Halim, PharmD, PhD; Daiichi Sankyo Pharma Development



**Contents**

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope.....1

2 Introduction.....1

3 Standard Precautions.....2

4 Terminology.....2

    4.1 Definitions .....2

    4.2 Abbreviations/Acronyms .....4

5 Preexamination Activities.....4

    5.1 Overview.....4

    5.2 Types of Urine Specimens.....4

    5.3 Instructing the Patient .....5

    5.4 Specimen Collection .....5

    5.5 Specimens From Infants and Small Children .....7

    5.6 Collection Containers .....8

    5.7 Specimen Transport and Storage .....9

    5.8 Acceptability of Specimens and Quality Assurance .....10

6 Testing Materials and Equipment .....11

    6.1 Materials .....11

    6.2 Equipment.....12

    6.3 Quality Control .....13

7 Macroscopic/Physical Urinalysis.....14

    7.1 Specimen Acceptability .....14

    7.2 Color, Clarity, and Odor .....15

    7.3 Urine Concentration (Specific Gravity).....15

8 Chemical Urinalysis – Manual.....16

    8.1 Precautions for Reagent Strip Use .....16

    8.2 Use of Reagent Strips .....16

    8.3 Confirmatory Tests .....17

9 Microscopic Urinalysis – Manual.....17

    9.1 Manual Microscopy .....18

    9.2 Identification of Microscopic Entities .....20

    9.3 Quality Assurance of the Microscopic Examination .....21

10 Automated Urinalysis .....21

    10.1 Automated Methods.....22

11 Quality Assurance.....24

    11.1 Introduction and Purpose .....24

**Contents (Continued)**

11.2 Recordkeeping .....24  
11.3 Procedure Manual .....24  
11.4 Proficiency Testing (External Quality Assessment) .....25  
11.5 Staff Competency .....25  
References.....26  
Appendix A. Representative Photomicrographs of Unstained Elements in Urine .....30  
Appendix B. Representative Photomicrographs of Stained Elements in Urine .....32  
Summary of Delegate Comments and Working Group Responses .....34  
The Quality Management System Approach .....40  
Related CLSI Reference Materials .....41



## Foreword

Important clinical information may be obtained from laboratory analysis of urine specimens. Much progress has been made since ancient times, when urine was poured on the ground and the attraction of insects to it indicated an abnormal specimen. Physical and chemical analysis of urine and microscopic examination of sediment, often performed today with sophisticated instrumentation, are as useful in physician office laboratories as they are in large clinical laboratories.

Urinalysis is a simple, rapid, and basic part of clinical laboratory testing. Its usefulness is proven in diagnosis of disease (diseases of the kidney, urinary tract, and liver, as well as metabolic disorders such as diabetes), in monitoring the effectiveness of treatment of chronic problems, and in screening for asymptomatic conditions.

Specimen collection is as important as the technical performance of urinalysis. Acceptable specimens improve the quality and reliability of urinalysis results. The working group believes this document is a practical guideline that is useful for all parties, laboratorians and nonlaboratorians alike, who are responsible for carrying out the procedure.

In this third edition, the scope was narrowed to performance of the traditional physical, chemical, and microscopic urinalysis. Previously, consideration was given to 24-hour urines and specialized urine measurand tests. New material on automated and semiautomated systems was added. Finally, some representative photomicrographs of urine sediment elements are included in this edition.

The working group believes this guideline will serve as a common reference point and facilitate communication between the site where the specimen is collected and the laboratory where the analysis is performed. By providing a clear picture of how specific actions can affect the test result or how one can give better instruction in specimen collection, the overall testing process will be improved.

## Key Words

Brightfield microscopy, dipstick, flow microscopy, formed elements, microscopic results, multiconstituent controls, pathologic conditions, physicochemical results, reagent strips, refractometer, sediment, slide microscopy, urinalysis



## Urinalysis; Approved Guideline—Third Edition

### 1 Scope

This document is written for laboratory and nonlaboratory personnel responsible for the collection, transport, and analysis of urine specimens. The guideline addresses macroscopic evaluation, chemical analysis, and microscopic examination of urine. A systematic outline for collecting, transporting, and storing specimens is included. The necessary materials and equipment used in the process are considered.

The focus of this guideline relates to urine collection and performance of the traditional, routine chemical and microscopic urinalysis. Unlike the previous edition, 24-hour urine collections are excluded, as are reference laboratory preanalytic requirements for specialized tests and detailed discussion of specific urine particle analyzer technologies.

Algorithmic approaches to evaluation of urine samples with respect to potential screening by reagent strip, with subsequent performance (or nonperformance) of culture, is beyond the scope of this guideline. See CLSI document EP12<sup>1</sup> for information on test comparisons for sensitivity, specificity, and predictive values in a clinical context.

### 2 Introduction

Urinalysis is the testing of urine with procedures commonly performed in an expeditious, reliable, accurate, safe, and cost-effective manner.

For the purposes of this guideline, the term “urinalysis” includes some or all of the following:

- macroscopic evaluation (eg, color, clarity);
- physical measurements (eg, volume for timed collections, specific gravity [SG]);
- chemical reagent strip or tablet testing; and
- microscopic examination.

Each laboratory, in consultation with its clinicians, should determine which procedures to use and the extent of the examination. These determinations should be based on an evaluation of known and published studies, as well as the type of patient population (eg, asymptomatic patient population screening yields few positive results, whereas in-hospital nephrology patients have a higher yield). The decision to perform microscopic examinations should be made by each individual laboratory based on its specific patient population.<sup>2-11</sup>

Urinalysis is performed for a variety of reasons, including:

- to aid in the diagnosis of disease;
- to screen a population for asymptomatic, congenital, or hereditary diseases (ie, to monitor wellness);
- to monitor the progress of disease; and
- to monitor the effectiveness or complications of therapy.